Crosslink Genetics Corporation is an emerging biotechnology company founded to capitalize on recent advances in understanding of molecular mechanisms of gene regulation. The firm's mission is to develop a novel class of drugs that regulate gene expression to improve the treatment of many chronic and fatal diseases caused by gene malfunction such as cancer, immune disorders and metabolic diseases. These new drugs - called Artificial Transcription Factors (ATFs) - are synthetic analogues of eukaryotic transcription factors, and represent a breakthrough in artificial gene regulation
